Thomas P Lodise1, Weihong Fan2, Katherine A Sulham2. 1. Albany College of Pharmacy and Health Sciences, Albany, New York. Electronic address: thomas.lodise@acphs.edu. 2. The Medicines Company, Parsippany, New Jersey.
Abstract
PURPOSE: Data indicate that acute bacterial skin and skin structure infection (ABSSSI) patients without major comorbidities can be managed effectively in the outpatient setting. Because most patients with ABSSSIs present to the emergency department, it is essential that clinicians identify candidates for outpatient treatment given the substantially higher costs associated with inpatient care. We examined the potential cost avoidance associated with shifting care from inpatient treatment with vancomycin to outpatient treatment with oritavancin for ABSSSI patients without major complications or comorbidities. METHODS: A decision analytic, cost-minimization model was developed to compare costs of inpatient vancomycin versus outpatient oritavancin treatment of ABSSSI patients with few or no comorbidities (Charlson Comorbidity Index score ≤1) and no life-threatening conditions presenting to emergency department. Hospital discharge data from the Premier Research Database was used to determine the costs associated with inpatient vancomycin treatment. FINDINGS: Mean costs for inpatient treatment with vancomycin ranged from $5973 to $9885, depending on Charlson Comorbidity Index score and presence of systemic symptoms. Switching an individual patient from inpatient vancomycin treatment to outpatient oritavancin treatment was estimated to save $1752.46 to $6475.87 per patient, depending on Charlson Comorbidity Index score, presence of systemic symptoms, and use of observation status. Assuming some patients may be admitted to the hospital after treatment with oritavancin, it is estimated that up to 38.12% of patients could be admitted while maintaining budget neutrality. IMPLICATIONS: This cost-minimization model indicates that use of oritavancin in the emergency department or observation setting is associated with substantial cost savings compared with inpatient treatment with vancomycin.
PURPOSE: Data indicate that acute bacterial skin and skin structure infection (ABSSSI) patients without major comorbidities can be managed effectively in the outpatient setting. Because most patients with ABSSSIs present to the emergency department, it is essential that clinicians identify candidates for outpatient treatment given the substantially higher costs associated with inpatient care. We examined the potential cost avoidance associated with shifting care from inpatient treatment with vancomycin to outpatient treatment with oritavancin for ABSSSI patients without major complications or comorbidities. METHODS: A decision analytic, cost-minimization model was developed to compare costs of inpatient vancomycin versus outpatientoritavancin treatment of ABSSSI patients with few or no comorbidities (Charlson Comorbidity Index score ≤1) and no life-threatening conditions presenting to emergency department. Hospital discharge data from the Premier Research Database was used to determine the costs associated with inpatient vancomycin treatment. FINDINGS: Mean costs for inpatient treatment with vancomycin ranged from $5973 to $9885, depending on Charlson Comorbidity Index score and presence of systemic symptoms. Switching an individual patient from inpatient vancomycin treatment to outpatientoritavancin treatment was estimated to save $1752.46 to $6475.87 per patient, depending on Charlson Comorbidity Index score, presence of systemic symptoms, and use of observation status. Assuming some patients may be admitted to the hospital after treatment with oritavancin, it is estimated that up to 38.12% of patients could be admitted while maintaining budget neutrality. IMPLICATIONS: This cost-minimization model indicates that use of oritavancin in the emergency department or observation setting is associated with substantial cost savings compared with inpatient treatment with vancomycin.
Authors: Thomas P Lodise; Mark Redell; Shannon O Armstrong; Katherine A Sulham; G Ralph Corey Journal: Open Forum Infect Dis Date: 2017-01-19 Impact factor: 3.835
Authors: Mark Redell; Greg Moeck; Christopher Lucasti; Stephanie Durso; Cynthia Kennedy; Karen Fusaro; Jeff Loutit; Michael Dudley Journal: Open Forum Infect Dis Date: 2018-03-19 Impact factor: 3.835
Authors: Lauren E Brownell; Meagan L Adamsick; Erin K McCreary; Joshua P Vanderloo; Erika J Ernst; Emily R Jackson; Lucas T Schulz Journal: Drugs Real World Outcomes Date: 2020-06
Authors: Kimberly Saddler; Jason Zhang; Jennifer Sul; Pruthvi Patel; Miriams Castro-Lainez; Mark L Stevens; Sheryl Kosler; Emily Lowery; Miguel Sierra-Hoffman Journal: PLoS One Date: 2021-03-18 Impact factor: 3.240